Bronchoscopic lung volume reduction imparts survival benefit in COPD patients: Study

Published On 2022-05-18 14:30 GMT   |   Update On 2022-05-18 14:30 GMT

Netherlands: The findings of a recent study led by Jorine E. Hartman and colleagues suggested that lowering lung capacity with bronchoscopy facing severe hyperinflation may result in a survival advantage in a group with a substantially shortened life expectancy. The findings of this study were published in Respiratory Medicine.Patients with severe Chronic Obstructive Pulmonary Disease (COPD)...

Login or Register to read the full article

Netherlands: The findings of a recent study led by Jorine E. Hartman and colleagues suggested that lowering lung capacity with bronchoscopy facing severe hyperinflation may result in a survival advantage in a group with a substantially shortened life expectancy. The findings of this study were published in Respiratory Medicine.

Patients with severe Chronic Obstructive Pulmonary Disease (COPD) can benefit greatly from bronchoscopic lung volume reduction (BLVR) therapies using coils or endobronchial valves. The possible influence of BLVR on survival, on the other hand, is less well recognised. As a result, the purpose of this study was to look at the survival rate in patients who are being considered for BLVR therapy and whether there is a difference in chance of survival between patients who receive BLVR treatment and those who do not.

This research included individuals with COPD who visited the hospital for a consultation to determine their potential for bronchoscopic lung volume reduction therapy and who had pulmonary function tests during this visit. Furthermore, the vital condition was confirmed.

The key findings of this study were as follow:

1. 1471 patients were enrolled in total (63% female, mean age 61 years).

2. A total of 531 patients (35%) died during follow-up, and the whole population's median survival time was 2694 days, or around 7.4 years.

3. The median survival time of patients who received BLVR was significantly longer than that of patients who did not receive BLVR (3133 days versus 2503 days), and BLVR was found to be an independent predictor of survival when other survival-influencing factors such as age, gender, or disease severity were controlled for.

In conclusion, the findings, when combined with the current research on both bronchoscopic and surgical lung volume reduction therapies, indicate that lowering lung volume in patients with COPD, severe hyperinflation, and decreased life expectancy may result in a survival advantage.

Reference:

Hartman, J. E., Welling, J. B. A., Klooster, K., Carpaij, O. A., Augustijn, S. W. S., & Slebos, D.-J. (2022). Survival in COPD patients treated with bronchoscopic lung volume reduction. In Respiratory Medicine (Vol. 196, p. 106825). Elsevier BV. https://doi.org/10.1016/j.rmed.2022.106825

Tags:    
Advertisement
Article Source : Respiratory Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News